Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Citigroup Inc. (C) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Citigroup Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $300.02 (market cap $39.89B), while Citigroup Inc. trades at $141.67 (market cap $240.13B). The key difference: Citigroup Inc. is far larger — about 6× Alnylam Pharmaceuticals, Inc.'s market cap, and Citigroup Inc. pays a 1.7% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | C | |
|---|---|---|
Market Cap | $39.89B | $240.13B |
Sector | Health | Financials |
52-Week High | $491.22 | $145.67 |
52-Week Low | $278.09 | $86.73 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Citigroup (C) trades at $140.60, up 0.75% today, with neutral technical signals and a consensus analyst price target of $153.15. Recent Q1 2026 earnings beat expectations with EPS of $3.06 versus $2.65. The stock shows improving fundamentals with revenue growth from $85.21B in 2025 to projected $88.3B in 2026 and net income margin expanding to 16.78%. Recent corporate developments include expansion into 24/7 USD clearing services and membership in London Precious Metals Clearing Limited, enhancing its global banking capabilities.
Outlook remains cautiously optimistic with 59% analyst buy ratings, though risks include volatile cash flows from operations and high debt levels. The upcoming Q2 2026 earnings report on July 14 is a key catalyst. Investment opportunity lies in continued execution on profitability improvements and global market expansion, balanced against macroeconomic sensitivity and competitive pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Citigroup Inc.
Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.
Read more on C →
